NantHealth (NH) Reports Q3 Loss of $0.10, Revenues Miss

NantHealth (NASDAQ: NH) reported Q3 EPS of ($0.10), versus ($0.13) reported last year. Revenue for the quarter came in at $22.3 million versus the consensus estimate of $24.61 million.

“We recently made two oral presentations at major medical congresses, highlighting the unique aspects of our liquid biopsy platform that are different from ctDNA platforms offered by Guardant Health, Foundation Medicine and other laboratories,” said Sandeep (Bobby) Reddy, M.D., Chief Medical Officer of NantHealth. “Only Liquid GPS can produce this type of data on chemotherapy selection and immunotherapy selection. Moreover, the review committees of two different organizations felt that this data was sufficiently important to warrant oral presentation. This further validates our belief that circulating RNA expression, not DNA alone, is the liquid biopsy technology that will transform medical practice.”

“We are pleased to report that total net revenue for the 2018 third quarter increased to $22.3 million, up from the comparable prior year period, as well as on a sequential quarterly basis,” said Bob Petrou, Interim Chief Financial Officer of NantHealth. “Looking ahead, the recent addition of two new executives to lead our strategy and business development, and global sales efforts will help us expand our business in both the U.S. and international markets.”

For earnings history and earnings-related data on NantHealth (NH) click here.

You May Also Be Interested In

• Grandstand Limited (GRSD) Tops Q2 EPS by 5c; Offers Guidance
• Caribou Biosciences, Inc. (CRBU) Tops Q2 EPS by 7c
• Vuzix Corp. (VUZI) Tops Q2 EPS by 1c